A 2018 screening of the ten most frequently encountered falsified peptide drugs on the Belgian market found purity levels ranging from just 5 to 75 percent for cysteine-containing compounds, alongside arsenic and lead contamination up to ten times the ICH toxicity limit (Janvier et al., published in Talanta, PubMed ID 30029448). A more recent analysis of semaglutide products sold online without a prescription found measured purity between 7.7 and 14.37 percent, against a labeled claim of 99 percent.
Why Purity Documentation Has Become a Procurement Requirement, Not a Courtesy
A compound that is 85 percent pure rather than the claimed 98 percent introduces an unknown mixture of truncated sequences, deletion products, and synthesis byproducts. The global high-performance liquid chromatography market was valued at roughly USD 5.44 billion in 2025 and is projected to reach USD 5.62 billion in 2026. In September 2025, the FDA issued more than 50 warning and untitled letters to companies compounding or manufacturing GLP-1 class peptides, with the total exceeding 100 letters within weeks.
What a Legitimate Certificate of Analysis Actually Contains
HPLC chromatogram data. A chromatogram showing peak area, retention time, and the proportion of total peak area attributable to the target compound is evidence, not just a claim.
Mass spectrometry confirmation. Mass spec verifies molecular weight against the expected mass, catching cases where a structurally similar but incorrect compound produces a clean HPLC trace.
Batch or lot number tied to the physical product. Analytical data that cannot be matched to the specific vial in hand is not useful for that vial.
Storage and stability information. Documentation that specifies storage conditions gives researchers a basis for judging whether a compound is still representative of its original CoA.
Third-Party Verification: Why In-House Testing Alone Is Not Sufficient
Third-party verification, meaning a CoA issued by a laboratory with no ownership stake in the product being tested, closes the incentive gap that in-house testing alone cannot.
Batch Consistency: The Question That Separates One-Time Testing From Ongoing Quality Control
Synthesis quality can drift with raw material sourcing, equipment calibration, and production volume, so researchers evaluating a supplier for repeat purchasing look for evidence of consistency across multiple batches.
How It Works in Practice
Researchers request the underlying chromatogram and mass spec files rather than accepting a summary figure, and confirm the batch number on the CoA matches the batch number on the product received. Bluum Peptides provides HPLC and mass spectrometry-backed Certificates of Analysis on a per-batch basis, which allows researchers to evaluate the documentation directly rather than relying on a general purity claim.
Where the Documentation Standard Is Heading
HPLC market growth in the mid-single-digit CAGR range reflects sustained investment in the exact instrumentation category that CoAs depend on. Regulatory scrutiny of the peptide supply chain has moved from sporadic to sustained.
Conclusion
The burden of proof continues to shift toward suppliers, and researchers positioned best are the ones already treating batch-specific, third-party-verifiable purity documentation as a non-negotiable input rather than a nice-to-have.
This article is intended for research and informational purposes only and does not constitute guidance for human use, diagnostic application, or therapeutic administration of any peptide compound.
Contributed posts are advertisements written by third parties who have paid Woman Around Town for publication.
